Effect of HSV-2 Suppressive Therapy on Sexual Behavior

• Status: Terminated
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine what effect suppressive therapy has on sexual behavior and quality of life among persons with genital herpes (HSV) who have multiple sex partners.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Washington
• Collaborator: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Acyclovir

Criteria

Inclusion Criteria:

• Age 18 years or older

• HSV-2 seropositive by Western blot OR documented culture positive for HSV-2 from anogenital site

• 2 or more vaginal or anal sex partners in the past 12 months

• Not currently in a monogamous sexual relationship of >= 6 months duration

• Willing and able to be randomized and comply with the study protocol

Exclusion Criteria:

• Pregnancy or intention to become pregnant within the next year

• Suppressive therapy with acyclovir, valacyclovir, or famciclovir within 2 weeks of enrollment/randomization

• 6 or more symptomatic herpes recurrences in the prior 12 months or in the 12 months prior to starting suppressive therapy if on suppressive therapy during the prior 12 months

• HIV seropositive or known immunocompromising medical condition. HIV negative test must be performed within 60 days of Visit 1 (enrollment/randomization). For current or former participants in HIV vaccine clinical trials for whom HIV vaccine-induced seropositivity potentially leading to vaccine study unblinding may be a concern, a report from the Seattle HVTU documenting that the participant is HIV uninfected based on HIV testing done within 60 days of Visit 1 will be accepted in lieu of HIV testing done at our clinic.

• Intention to move from the Seattle area within the next year

• Known allergy, intolerance, or medical contraindication to acyclovir

• Inability to understand, speak, and read English